Britain and America have concluded a important commercial pact that will maintain no duties on British drug products entering the American market.
The Terms of the Pact
As part of the deal, the UK has pledged to raise spending on pharmaceuticals through the NHS. This pledge ensures that duties on these crucial goods will be held at zero for a duration of 36 months.
This agreement is in response to earlier statements to significantly raise import taxes on patented pharmaceutical imports, with increases floated as high as 100%.
"This agreement with the United Kingdom reinforces the international landscape for cutting-edge drugs and brings long-overdue equity to transatlantic medicine commerce," a statement declared.
Trade Importance
Medicines constitute one of the the United Kingdom's largest export categories to the US, which is easily the primary buyer for large companies like GSK and AstraZeneca.
Statistics reveal that in the one-year period leading up to the third quarter, the UK exported pharmaceutical products totaling over eleven billion pounds to the US. This amount accounted for 17.4% of total UK exports in that timeframe.
"This agreement safeguards employment, stimulates investment and sets the stage for the UK to establish itself as a international leader for biotech and pharma," a minister commented.
Detailed UK Commitments
The deal involves several notable commitments from the UK:
- Revised Affordability Limit: The UK will increase the affordability limit at which it considers new medicines to be unaffordable by twenty-five percent.
- Boosted Medicine Funding: There is a target to increase overall health service expenditure on drugs from 0.3 percent of the national economy to 0.6 percent over the following ten-year period.
- Rebate Cap: The sum drug companies must refund to the NHS to control costs will be capped at 15%. Last year, repayments exceeded 20%.
Industry Background
The pact follows a protracted row between the drug companies and the UK government over drug pricing and NHS adoption.
This friction were exacerbated by claims that American consumers were charged significantly more for the same drugs than patients in the Britain and the EU.
In recent months, several large drug company projects in the UK have been halted or scrapped, while substantial expansions have been directed toward American operations.
A senior figure stated that the NHS had to increase expenditure on treatments, noting that its spending on drugs had shrunk as a proportion of its total funding over the last ten years.
